केरल की साँप काटने की संकट: एएसवी उपयोग, SARPA कार्यक्रम में अंतराल और त्वरित निदान की आवश्यकता

<p>Kerala faces a growing public‑health challenge as snakebite deaths rise despite the widespread availability of <span class="key-term" data-definition="Anti‑snake venom — serum containing antibodies used to neutralise snake venom; crucial for managing envenomation cases (GS3: Health).">ASV</span>. The problem stems from ecological factors, clinical decision‑making uncertainties, and infrastructural shortfalls that together undermine the effectiveness of treatment.</p> <h3>Key Developments</h3> <ul> <li>Hotter pre‑monsoon summers drive <span class="key-term" data-definition="Ectothermic — organisms that rely on external heat sources to regulate body temperature; snakes are ectothermic, influencing their behaviour (GS3: Biology).">ectothermic</span> snakes into homes and storerooms, increasing human contact.</li> <li>The <strong>Indian Council of Medical Research (ICMR)</strong> has highlighted the flaws of the current <span class="key-term" data-definition="Syndromic approach — diagnosing based on clinical symptoms without laboratory confirmation; used for snakebite but may delay treatment (GS3: Health).">syndromic approach</span>, which relies on symptoms that appear after irreversible tissue damage.</li> <li>Kerala’s <span class="key-term" data-definition="SARPA — State Action for Rescue and Prevention of Accidents, a Kerala programme to professionalise snake rescue and awareness (GS2: Governance).">SARPA</span> initiative has made snakebite a notifiable disease and launched rescue‑training programmes, yet mortality remains high.</li> <li>Administration of <span class="key-term" data-definition="Anti‑snake venom — serum containing antibodies used to neutralise snake venom; crucial for managing envenomation cases (GS3: Health).">ASV</span> carries a risk of <span class="key-term" data-definition="Anaphylaxis — severe, rapid allergic reaction that can be fatal; a risk when administering ASV (GS3: Health).">anaphylaxis</span>, complicating treatment decisions.</li> </ul> <h3>Important Facts</h3> <p>India records nearly 50% of global snakebite incidents, with agricultural workers and children most vulnerable. Kerala alone hosts over 100 snake species, including the “<strong>Big Four</strong>” venomous snakes – the common krait, Russell’s viper, saw‑scaled viper and spectacled cobra. Approximately 70% of bites involve non‑venomous snakes, and half of the venomous bites are “dry” (no venom injected), meaning many patients do not require <span class="key-term" data-definition="Anti‑snake venom — serum containing antibodies used to neutralise snake venom; crucial for managing envenomation cases (GS3: Health).">ASV</span>. However, the lack of a rapid diagnostic kit forces clinicians to rely on symptom‑based assessment, often leading to delayed or unnecessary treatment.</p> <p>Compounding the issue are scarce ICU beds, limited ventilator backups, inadequate training in managing <span class="key-term" data-definition="Anaphylaxis — severe, rapid allergi